Comparing the current results to its competitors, Conmed reported Revenue increase in the 2 quarter 2026 by 0.33 % year on year. The revenue growth was below Conmed's competitors' average revenue growth of 8.82 %, achieved in the same quarter.
Conmed's Comment on Competition and Industry Peers
The company operates globally in the orthopedic and general surgery medical device markets. Its competitors in orthopedic products include Smith & Nephew, plc; Arthrex, Inc.; Stryker Corporation; Johnson & Johnson: DePuy Mitek, Inc.; Zimmer Biomet, Inc.; Globus Medical, Inc.; and Treace Medical Concepts, Inc. In powered surgical instruments, competitors are Stryker Corporation; Medtronic plc; Johnson & Johnson: DePuy Synthes, Inc.; and Zimmer Biomet, Inc. For general surgery products, competitors include Medtronic plc; Johnson & Johnson: Ethicon Endo-Surgery, Inc.; Stryker Endoscopy; Olympus Corporation; ERBE Elektromedizin GmbH; and Applied Medical Resources Corporation. In advanced endoscopic technologies, competitors are Boston Scientific Corporation - Endoscopy; Cook Medical, Inc.; Merit Medical Endotek; Olympus Corporation; STERIS Corporation - U.S. Endoscopy; Cantel Medical - Medivators, Inc.; Cardinal Health Inc.; and 3M Company. The company previously held an exclusive distribution agreement with W. L. Gore & Associates, Inc. for the Gore® VIABIL® Biliary Endoprosthesis in the U.S. and Canada through 2026 but chose to end the agreement early. The company maintains that it has suitable product offerings and market share to compete effectively amid technological advances and changes in the global market.
With modest revenue growth of 0.33 % within Overall company, Conmed Corporation failed to increase sales with the same pace, like most of company's peers within this division. << More on CNMD Market Share.
*Market share is calculated based on total revenue.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Medinotec Inc is a medical technology company that operates on a business model focused on developing and providing innovative healthcare solutions, such as medical devices and software, to improve patient care and outcomes. Their products and services cater to healthcare professionals and institutions, offering advanced technology solutions in the medical field.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Intuitive Surgical Incs business model focuses on delivering robotic surgical systems, particularly the da Vinci Surgical System, which facilitates minimally invasive surgeries. Revenue is generated through system sales, instruments, accessories, and services, including training and maintenance for healthcare providers.
Sources:
Conmed Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Conmed Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
